GT
TVRD

Glenmede Trust’s Tvardi Therapeutics TVRD Stock Holding History

Glenmede Trust’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6
Closed -$2K – 2312
2020
Q3 		$2K Hold
6
– – ﹤0.01% 2298
2020
Q2 		$3K Buy
+6
New +$3.31K ﹤0.01% 2202
2017
Q4 		– Sell
-7
Closed -$3K – 2815
2017
Q3 		$3K Buy
+7
New +$3.5K ﹤0.01% 2509

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Glenmede Trust's TVRD Position: Q4 2020 in Review

Glenmede Trust sold out of Tvardi Therapeutics (TVRD) in Q4 2020, closing a stake of 6 shares — an estimated $2K sold.

Glenmede Trust first reported a position in TVRD in Q3 2017 and held it in 3 quarters. The position peaked at $3K in Q2 2020. 155 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

  • Glenmede Trust reported no remaining Tvardi Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 6 Tvardi Therapeutics shares in Q4 2020, an estimated $2K.
  • Glenmede Trust first reported a position in Tvardi Therapeutics in Q3 2017 and held it in 3 quarters.
  • Glenmede Trust's Tvardi Therapeutics position peaked at $3K in Q2 2020.
  • 155 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.